Tobira Therapeutics, a biotech developing an immunotherapy treatment for liver disease (NASH) and HIV, filed on Monday with the SEC to raise up to $69 million in an initial public offering. The San Francisco, CA-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol TBRA. BMO Capital Markets, JMP Securities and Oppenheimer are the joint bookrunners on the deal. No pricing terms were disclosed.
